Transrectal ultrasound examination of the prostate: complications and acceptance by patients.
Transrectal ultrasound scan (TRUS) of the prostate was performed on 511 patients, 391 of whom also underwent between 1 and 5 transrectal 1.2 mm core biopsies. The infection rate in the whole group was 4.1%; 32% of the patients were given antibiotic prophylaxis with norfloxacin 400 mg twice daily for 1 week and in this group the infection rate was 0.8%. In the remaining patients, who received 400 mg norfloxacin at the time of biopsy and another 400 mg the same evening, the infection rate was 5.6%. The only risk factor identified for post-biopsy infection was steroid medication. Only minor discomfort (or none at all) was reported by 95% of patients during the examination procedure. If TRUS was combined with core biopsy 92% reported either minor or no discomfort. Of 78 patients who experienced both finger-guided fine needle aspiration biopsy and TRUS-guided core biopsy 82% preferred the latter procedure. TRUS and core biopsy proved acceptable to most patients. Antibiotic treatment with 2 tablets of norfloxacin failed to prevent infection.
Aus
G
G
Department of Urology, Ostra Hospital, Gothenburg, Sweden.
Hermansson
C G
CG
Hugosson
J
J
Pedersen
K V
KV
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000517:prevention & control; D001707:Biopsy, Needle / Q000009:adverse effects / Q000379:methods / Q000523:psychology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009643:Norfloxacin / Q000627:therapeutic use; D010342:Patient Acceptance of Health Care; D011467:Prostate / Q000000981:diagnostic imaging* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D012307:Risk Factors; D014463:Ultrasonography
D009643:Norfloxacin